Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q4 FY2022 Earnings Presentation
20 slides from Jubilant Pharmova's earnings presentation, May 27, 2022
Slide 1: Financial Results Quarter & Year Ended March 31, 2022
Financial Results Quarter & Year Ended March 31, 2022
Slide 2: Conference Call Details
Conference Call Details Date : May 27, 2022 Time : 05:00 pm IST +91 22 6280 1141 Primary Number +91 22 7115 8042 USA: 1 866 746 2133 UK: 0 808 101 1573 Toll Free Number Singapore: 800 101 2045 Hong Kong: 800 964 448 Replay: May 27 to June 03, 2022 Dial-in: +91 22 7194 5757 / +91 22 6663 5757 Playbac
Slide 3: Chairmen's Message
Chairmen’s Message Jubilant Pharmova Q4 and FY22 Key Financial Parameters Particulars1,2 Q4'FY21 Q4'FY22 FY21 FY22 Total Revenue from Operations 1,580 1,528 6,099 6,130 Reported EBITDA 381 244 1,414 1,168 Reported EBITDA margin (%) 24.1% 16.0% 23.2% 19.0% Profit After Tax 173 59 574 413 PAT margin (
Slide 4: Q4'FY22 Results Analysis
4 Jonazmova Q4'FY22 Results Analysis
Slide 5: Q4'FY22 Financial Highlights
Q4'FY22 Financial Highlights Particulars1,2 Q4'FY21 Q4'FY22 YoY (%) Revenue Revenue was at Rs 1,528 Crore versus Rs 1,580 Crore in Q4'FY21 Pharmaceuticals 1,486 1,380 -7% • Pharmaceuticals revenue at Rs 1,380 Crore as compared to Contract Research and Development Services 94 142 51% Rs 1,486 Crore
Slide 6: Pharmaceuticals Segment Highlights – Q4'FY22 (1/2)
Pharmaceuticals Segment Highlights – Q4'FY22 (1/2) Particulars1,2 Q4'FY21 Q4'FY22 YoY (%) Pharmaceuticals revenue at Rs 1,380 Crore vs. Rs 1,486 Crore in Q4’FY21 Revenue 1,486 1,380 -7% Specialty Pharmaceuticals3 Specialty Pharma 602 695 15% CDMO 574 466 (19%) • Radiopharma business witnessed impr
Slide 7: Pharmaceuticals Segment Highlights – Q4'FY22 (2/2)
Pharmaceuticals Segment Highlights – Q4'FY22 (2/2) USFDA Inspection Details CDMO1 Facility Last Inspection • CMO business is operating at normal pre-pandemic levels now, COVID related Montreal, Radiopharma Sep, 2017 one-off deals tapered off as indicated earlier Montreal, CMO May, 2018 • API busines
Slide 8: Contract Research and Development Services – Q4'FY22
Contract Research and Development Services – Q4'FY22 Particulars1,2 Q4'FY21 Q4'FY22 YoY (%) Contract Research and Development Services business through Revenue 94 142 51% Jubilant Biosys Limited provides innovative and collaborative research and development services from world class research Repor
Slide 9: Jubilant Therapeutics: Clinical stage precision therapeutics company
Jubilant Therapeutics: Clinical stage precision therapeutics company addressing significant unmet medical needs in oncology and autoimmune diseases 88
Slide 10: Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases
Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases 99
Slide 11: FY22 Results Analysis
4 Jonazmova FY22 Results Analysis 10
Slide 12: FY22 Financial Highlights
FY22 Financial Highlights Particulars1,2 FY21 FY22 YoY (%) Revenue Revenue was Rs 6,130 Crore versus Rs 6,099 Crore in FY21 Pharmaceuticals 5,790 5,651 -2% • Pharmaceuticals revenue at Rs 5,651 Crore as compared to Rs Contract Research and Development Services 305 457 50% Proprietary Novel Drugs 4
Slide 13: Contract Research and Development Services – FY22
Contract Research and Development Services – FY22 Particulars1,2 FY21 FY22 YoY (%) Contract Research and Development Services business through Revenue 305 457 50% Jubilant Biosys Limited provides innovative and collaborative research and development services from world class research Reported EBIT
Slide 14: Debt Profile
Debt Profile Particulars 31-03-21 30-09-21 31-12-21 31-03-22 Gross Debt (Rs. Crs) (Rs. Crs) (Rs. Crs) (Rs. Crs) Long Term 2,580 2,635 2,825 2,874 Short Term 20 91 33 64 Total 2,600 2,726 2,859 2,938 Cash & Equivalent 671.3 862.9 1,022 984 Net Debt (On a Constant Currency Basis) 1,928 1,823 1,792 1,8
Slide 15: Business outlook
Business outlook Pharma: In radiopharma, we continue to build a long term pipeline of diagnostic and therapeutic radiopharmaceuticals and are executing a turnaround plan of radiopharmacies, which is showing encouraging results. I131 MIBG clinical trials underway with launch expected in FY25. Mediu
Slide 16: Update on API Demerger
Update on API Demerger • In July 2021, the Board of Directors of Jubilant Pharmova Limited (JPM) approved demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited(JGL) and vesting of the same with JPM, on a going concern basis, to be implemented through a sche
Slide 17: The reorganisation will ensure presence across the value chain
The reorganisation will ensure presence across the value chain Patent Life On -patent Off Patent Type of Discovery Development Commercialization Service Research Discovery Preclinical Clinical Registration Manufacturing Drug Drug discovery DMPK Phase I trials Approval Pharmacological Permission to O
Slide 18: Appendix
4 Jonazmova Appendix 17
Slide 19: Income Statement – Q4'FY22 & FY22
Income Statement – Q4’FY22 & FY22 Particulars1,2 Q4'FY21 Q4'FY22 YoY (%) FY21 FY22 YoY (%) Total Revenue from Continuing Operations Pharmaceuticals 1,486 1,380 (7%) 5,790 5,651 (2%) Contract Research and Development Services 94 142 51% 305 457 50% Proprietary Novel Drugs 0 0 - 4 2 (50%) Unallocable
Slide 20: For more information
For more information For Investors: Vineet V Mayer Siddharth Rangnekar Ph: +91 120 436 1103 CDR India E-mail: vineet.mayer@jubl.com Ph: +91 +91 9769919966 E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1062 Madison Public Relations E-mail: sudhakar.safaya@j